1.3M XNAS Volume
XNAS 20 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Iain M. Brown | SVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 5,617 | 16,854 | - | - | Restricted Stock Unit Award | |
| Iain M. Brown | SVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 5,617 | 150,690 (0%) | 0% | - | Ordinary Shares | |
| Iain M. Brown | SVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.80 per share. | 26 Feb 2025 | 2,494 | 148,196 (0%) | 0% | 34.8 | 86,779 | Ordinary Shares |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 6,866 | 20,598 | - | - | Restricted Stock Unit Award | |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 6,866 | 207,304 (0%) | 0% | - | Ordinary Shares | |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.80 per share. | 26 Feb 2025 | 3,049 | 204,255 (0%) | 0% | 34.8 | 106,090 | Ordinary Shares |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.80 per share. | 26 Feb 2025 | 3,049 | 77,740 (0%) | 0% | 34.8 | 106,090 | Ordinary Shares |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 6,866 | 80,789 (0%) | 0% | - | Ordinary Shares | |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 6,866 | 20,598 | - | - | Restricted Stock Unit Award | |
| Christian Todd Nichols | SVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.80 per share. | 26 Feb 2025 | 2,402 | 92,875 (0%) | 0% | 34.8 | 83,578 | Ordinary Shares |
| Christian Todd Nichols | SVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 5,409 | 16,229 | - | - | Restricted Stock Unit Award | |
| Christian Todd Nichols | SVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 5,409 | 95,277 (0%) | 0% | - | Ordinary Shares | |
| Blair C. Jackson | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 8,322 | 205,063 (0%) | 0% | - | Ordinary Shares | |
| Blair C. Jackson | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.80 per share. | 26 Feb 2025 | 3,695 | 201,368 (0%) | 0% | 34.8 | 128,568 | Ordinary Shares |
| Blair C. Jackson | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 8,322 | 24,967 | - | - | Restricted Stock Unit Award | |
| Samuel J. Parisi | VP, Finance (Interim PAO) | Sale of securities on an exchange or to another person at price $ 34.00 per share. | 26 Feb 2025 | 1,938 | 7,717 (0%) | 0% | 34 | 65,892 | Ordinary Shares |
| Samuel J. Parisi | VP, Finance (Interim PAO) | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 2,746 | 10,463 (0%) | 0% | - | Ordinary Shares | |
| Samuel J. Parisi | VP, Finance (Interim PAO) | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 2,746 | 8,240 | - | - | Restricted Stock Unit Award | |
| Samuel J. Parisi | VP, Finance (Interim PAO) | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.79 per share. | 26 Feb 2025 | 808 | 9,655 (0%) | 0% | 34.8 | 28,114 | Ordinary Shares |
| Iain M. Brown | SVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 7,109 | 144,989 (0%) | 0% | - | Ordinary Shares | |
| Iain M. Brown | SVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 5,825 | 11,650 | - | - | Restricted Stock Unit Award | |
| Iain M. Brown | SVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 7,109 | 0 | - | - | Restricted Stock Unit Award | |
| Iain M. Brown | SVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.32 per share. | 22 Feb 2025 | 2,587 | 145,073 (0%) | 0% | 35.3 | 91,373 | Ordinary Shares |
| Iain M. Brown | SVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 5,825 | 147,660 (0%) | 0% | - | Ordinary Shares | |
| Iain M. Brown | SVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.32 per share. | 22 Feb 2025 | 3,154 | 141,835 (0%) | 0% | 35.3 | 111,399 | Ordinary Shares |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 7,432 | 199,463 (0%) | 0% | - | Ordinary Shares | |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.32 per share. | 22 Feb 2025 | 3,300 | 196,163 (0%) | 0% | 35.3 | 116,556 | Ordinary Shares |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 7,689 | 203,852 (0%) | 0% | - | Ordinary Shares | |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.32 per share. | 22 Feb 2025 | 3,414 | 200,438 (0%) | 0% | 35.3 | 120,582 | Ordinary Shares |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 7,432 | 0 | - | - | Restricted Stock Unit Award | |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 7,689 | 15,379 | - | - | Restricted Stock Unit Award | |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.32 per share. | 22 Feb 2025 | 5,452 | 69,648 (0%) | 0% | 35.3 | 192,565 | Ordinary Shares |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 7,689 | 15,379 | - | - | Restricted Stock Unit Award | |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 12,279 | 0 | - | - | Restricted Stock Unit Award | |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.32 per share. | 22 Feb 2025 | 3,414 | 73,923 (0%) | 0% | 35.3 | 120,582 | Ordinary Shares |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 7,689 | 77,337 (0%) | 0% | - | Ordinary Shares | |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 12,279 | 75,100 (0%) | 0% | - | Ordinary Shares | |
| Christian Todd Nichols | SVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 6,408 | 92,714 (0%) | 0% | - | Ordinary Shares | |
| Christian Todd Nichols | SVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 6,408 | 12,815 | - | - | Restricted Stock Unit Award | |
| Christian Todd Nichols | SVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 7,109 | 0 | - | - | Restricted Stock Unit Award | |
| Christian Todd Nichols | SVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.32 per share. | 22 Feb 2025 | 2,846 | 89,868 (0%) | 0% | 35.3 | 100,521 | Ordinary Shares |
| Christian Todd Nichols | SVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.32 per share. | 22 Feb 2025 | 3,157 | 86,306 (0%) | 0% | 35.3 | 111,505 | Ordinary Shares |
| Christian Todd Nichols | SVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 7,109 | 89,463 (0%) | 0% | - | Ordinary Shares | |
| Blair C. Jackson | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 9,694 | 196,188 (0%) | 0% | - | Ordinary Shares | |
| Blair C. Jackson | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.32 per share. | 22 Feb 2025 | 4,305 | 191,883 (0%) | 0% | 35.3 | 152,053 | Ordinary Shares |
| Blair C. Jackson | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 8,738 | 200,621 (0%) | 0% | - | Ordinary Shares | |
| Blair C. Jackson | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.32 per share. | 22 Feb 2025 | 3,880 | 196,741 (0%) | 0% | 35.3 | 137,042 | Ordinary Shares |
| Blair C. Jackson | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 9,694 | 0 | - | - | Restricted Stock Unit Award | |
| Blair C. Jackson | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 8,738 | 17,476 | - | - | Restricted Stock Unit Award | |
| Samuel J. Parisi | VP, Finance (Interim PAO) | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 3,114 | 0 | - | - | Restricted Stock Unit Award | |
| Samuel J. Parisi | VP, Finance (Interim PAO) | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 2,284 | 4,567 | - | - | Restricted Stock Unit Award | |
| Samuel J. Parisi | VP, Finance (Interim PAO) | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.32 per share. | 22 Feb 2025 | 672 | 11,460 (0%) | 0% | 35.3 | 23,735 | Ordinary Shares |
| Samuel J. Parisi | VP, Finance (Interim PAO) | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 2,284 | 12,132 (0%) | 0% | - | Ordinary Shares | |
| Samuel J. Parisi | VP, Finance (Interim PAO) | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.32 per share. | 22 Feb 2025 | 983 | 9,848 (0%) | 0% | 35.3 | 34,720 | Ordinary Shares |
| Samuel J. Parisi | VP, Finance (Interim PAO) | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 3,114 | 10,831 (0%) | 0% | - | Ordinary Shares | |
| Samuel J. Parisi | VP, Finance (Interim PAO) | Sale of securities on an exchange or to another person at price $ 35.26 per share. | 22 Feb 2025 | 3,743 | 7,717 (0%) | 0% | 35.3 | 131,978 | Ordinary Shares |
| Richard F. Pops | Director, Director and CEO, Alkermes plc | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 293,921 | 293,921 | - | - | Employee Stock Option (Right to Buy) | |
| Iain M. Brown | SVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 6,354 | 6,355 | - | - | Restricted Stock Unit Award | |
| Iain M. Brown | SVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 6,354 | 139,749 (0%) | 0% | - | Ordinary Shares | |
| Iain M. Brown | SVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.90 per share. | 18 Feb 2025 | 1,869 | 137,880 (0%) | 0% | 35.9 | 67,097 | Ordinary Shares |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 6,354 | 6,355 | - | - | Restricted Stock Unit Award | |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 63,991 | 63,991 | - | - | Employee Stock Option (Right to Buy) | |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 30,692 | 30,692 | - | - | Restricted Stock Unit Award | |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 6,354 | 194,853 (0%) | 0% | - | Ordinary Shares | |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.90 per share. | 18 Feb 2025 | 2,822 | 192,031 (0%) | 0% | 35.9 | 101,310 | Ordinary Shares |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 8,896 | 66,771 (0%) | 0% | - | Ordinary Shares | |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 30,692 | 30,692 | - | - | Restricted Stock Unit Award | |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 63,991 | 63,991 | - | - | Employee Stock Option (Right to Buy) | |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 8,896 | 8,897 | - | - | Restricted Stock Unit Award | |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.90 per share. | 18 Feb 2025 | 3,950 | 62,821 (0%) | 0% | 35.9 | 141,805 | Ordinary Shares |
| Christian Todd Nichols | SVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 24,182 | 24,182 | - | - | Restricted Stock Unit Award | |
| Christian Todd Nichols | SVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 50,417 | 50,417 | - | - | Employee Stock Option (Right to Buy) | |
| Christian Todd Nichols | SVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 6,354 | 6,355 | - | - | Restricted Stock Unit Award | |
| Christian Todd Nichols | SVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.90 per share. | 18 Feb 2025 | 1,869 | 82,354 (0%) | 0% | 35.9 | 67,097 | Ordinary Shares |
| Christian Todd Nichols | SVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 6,354 | 84,223 (0%) | 0% | - | Ordinary Shares | |
| Blair C. Jackson | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 8,896 | 190,444 (0%) | 0% | - | Ordinary Shares | |
| Blair C. Jackson | EVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 37,203 | 37,203 | - | - | Restricted Stock Unit Award | |
| Blair C. Jackson | EVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 77,565 | 77,565 | - | - | Employee Stock Option (Right to Buy) | |
| Blair C. Jackson | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 8,896 | 8,897 | - | - | Restricted Stock Unit Award | |
| Blair C. Jackson | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.90 per share. | 18 Feb 2025 | 3,950 | 186,494 (0%) | 0% | 35.9 | 141,805 | Ordinary Shares |
| Samuel J. Parisi | VP, Finance (Interim PAO) | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 2,033 | 9,750 (0%) | 0% | - | Ordinary Shares | |
| Samuel J. Parisi | VP, Finance (Interim PAO) | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 12,287 | 12,287 | - | - | Employee Stock Option (Right to Buy) | |
| Samuel J. Parisi | VP, Finance (Interim PAO) | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 11,965 | 11,965 | - | - | Restricted Stock Unit Award | |
| Samuel J. Parisi | VP, Finance (Interim PAO) | Sale of securities on an exchange or to another person at price $ 35.69 per share. | 18 Feb 2025 | 1,327 | 7,717 (0%) | 0% | 35.7 | 47,361 | Ordinary Shares |
| Samuel J. Parisi | VP, Finance (Interim PAO) | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 2,033 | 2,034 | - | - | Restricted Stock Unit Award | |
| Samuel J. Parisi | VP, Finance (Interim PAO) | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.90 per share. | 18 Feb 2025 | 706 | 9,044 (0%) | 0% | 35.9 | 25,345 | Ordinary Shares |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.34 per share. | 12 Feb 2025 | 111,630 | 262,796 (0%) | 0% | 19.3 | 2,158,924 | Ordinary Shares |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.69 per share. | 12 Feb 2025 | 171,813 | 90,983 (0%) | 0% | 32.7 | 5,616,808 | Ordinary Shares |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 108,833 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 111,630 | 50,104 | - | - | Employee Stock Option (Right to Buy) | |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 87,566 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 36.02 per share. | 12 Feb 2025 | 108,833 | 57,875 (0%) | 0% | 36.0 | 3,920,001 | Ordinary Shares |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 34.02 per share. | 12 Feb 2025 | 35,586 | 166,708 (0%) | 0% | 34.0 | 1,210,696 | Ordinary Shares |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.59 per share. | 12 Feb 2025 | 35,586 | 202,294 (0%) | 0% | 24.6 | 875,060 | Ordinary Shares |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.93 per share. | 12 Feb 2025 | 108,833 | 166,708 (0%) | 0% | 31.9 | 3,475,038 | Ordinary Shares |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 35,586 | 71,172 | - | - | Employee Stock Option (Right to Buy) | |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 33.27 per share. | 12 Feb 2025 | 33,108 | 57,875 (0%) | 0% | 33.3 | 1,101,470 | Ordinary Shares |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.03 per share. | 12 Feb 2025 | 87,566 | 151,166 (0%) | 0% | 20.0 | 1,753,947 | Ordinary Shares |
| Richard F. Pops | Director, Director and CEO, Alkermes plc | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 190,640 | 1,370,315 (0%) | 0% | - | Ordinary Shares | |
| Richard F. Pops | Director, Director and CEO, Alkermes plc | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.39 per share. | 06 Feb 2025 | 79,925 | 1,290,390 (0%) | 0% | 31.4 | 2,508,846 | Ordinary Shares |
| Iain M. Brown | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 24,565 | 140,909 (0%) | 0% | - | Ordinary Shares | |
| Iain M. Brown | SVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.39 per share. | 06 Feb 2025 | 7,514 | 133,395 (0%) | 0% | 31.4 | 235,864 | Ordinary Shares |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 32,350 | 198,251 (0%) | 0% | - | Ordinary Shares | |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.39 per share. | 06 Feb 2025 | 9,752 | 188,499 (0%) | 0% | 31.4 | 306,115 | Ordinary Shares |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.39 per share. | 06 Feb 2025 | 15,083 | 63,600 (0%) | 0% | 31.4 | 473,455 | Ordinary Shares |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 34,393 | 78,683 (0%) | 0% | - | Ordinary Shares | |
| Christian Todd Nichols | SVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.39 per share. | 06 Feb 2025 | 7,399 | 77,869 (0%) | 0% | 31.4 | 232,255 | Ordinary Shares |
| Christian Todd Nichols | SVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 24,565 | 85,268 (0%) | 0% | - | Ordinary Shares | |
| Blair C. Jackson | EVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 34,393 | 192,195 (0%) | 0% | - | Ordinary Shares | |
| Blair C. Jackson | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.39 per share. | 06 Feb 2025 | 10,647 | 181,548 (0%) | 0% | 31.4 | 334,209 | Ordinary Shares |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.03 per share. | 30 Jan 2025 | 29,156 | 76,732 (0%) | 0% | 20.0 | 583,995 | Ordinary Shares |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.34 per share. | 30 Jan 2025 | 26,589 | 103,321 (0%) | 0% | 19.3 | 514,231 | Ordinary Shares |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.59 per share. | 30 Jan 2025 | 23,542 | 126,863 (0%) | 0% | 24.6 | 578,898 | Ordinary Shares |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.82 per share. | 30 Jan 2025 | 18,345 | 145,208 (0%) | 0% | 26.8 | 492,013 | Ordinary Shares |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.05 per share. | 30 Jan 2025 | 100,918 | 44,290 (0%) | 0% | 32.0 | 3,234,382 | Ordinary Shares |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 29,156 | 87,566 | - | - | Employee Stock Option (Right to Buy) | |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 26,589 | 161,734 | - | - | Employee Stock Option (Right to Buy) | |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 23,542 | 106,758 | - | - | Employee Stock Option (Right to Buy) | |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 18,345 | 92,271 | - | - | Employee Stock Option (Right to Buy) | |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.03 per share. | 09 Dec 2024 | 12,452 | 72,182 (0%) | 0% | 20.0 | 249,414 | Ordinary Shares |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 12,090 | 188,323 | - | - | Employee Stock Option (Right to Buy) | |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 12,411 | 110,616 | - | - | Employee Stock Option (Right to Buy) | |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 12,044 | 130,300 | - | - | Employee Stock Option (Right to Buy) | |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 12,452 | 116,722 | - | - | Employee Stock Option (Right to Buy) | |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.07 per share. | 09 Dec 2024 | 61,151 | 47,576 (0%) | 0% | 32.1 | 1,961,406 | Ordinary Shares |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.82 per share. | 09 Dec 2024 | 12,411 | 108,727 (0%) | 0% | 26.8 | 332,863 | Ordinary Shares |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.59 per share. | 09 Dec 2024 | 12,044 | 96,316 (0%) | 0% | 24.6 | 296,162 | Ordinary Shares |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.34 per share. | 09 Dec 2024 | 12,090 | 84,272 (0%) | 0% | 19.3 | 233,821 | Ordinary Shares |
| Cato T. Laurencin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2024 | 4,163 | 23,971 (0%) | 0% | - | Ordinary Shares | |
| Cato T. Laurencin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2024 | 2,691 | 16,142 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Cato T. Laurencin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2024 | 4,163 | 0 | - | - | Restricted Stock Unit Award | |
| Cato T. Laurencin | Director | Sale of securities on an exchange or to another person at price $ 31.85 per share. | 08 Dec 2024 | 2,691 | 23,013 (0%) | 0% | 31.8 | 85,708 | Ordinary Shares |
| Cato T. Laurencin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.52 per share. | 08 Dec 2024 | 2,691 | 25,704 (0%) | 0% | 22.5 | 60,601 | Ordinary Shares |
| Cato T. Laurencin | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.46 per share. | 08 Dec 2024 | 958 | 23,013 (0%) | 0% | 31.5 | 30,139 | Ordinary Shares |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 31.50 per share. | 05 Dec 2024 | 9,221 | 59,730 (0%) | 0% | 31.5 | 290,462 | Ordinary Shares |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.77 per share. | 04 Dec 2024 | 14,349 | 68,951 (0%) | 0% | 30.8 | 441,550 | Ordinary Shares |
| Christian Nichols Todd | SVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 29.15 per share. | 27 Nov 2024 | 5,208 | 60,703 (0%) | 0% | 29.1 | 151,813 | Ordinary Shares |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.03 per share. | 11 Nov 2024 | 43,058 | 142,296 (0%) | 0% | 20.0 | 862,452 | Ordinary Shares |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2024 | 43,058 | 129,174 | - | - | Employee Stock Option (Right to Buy) | |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.08 per share. | 11 Nov 2024 | 58,996 | 83,300 (0%) | 0% | 30.1 | 1,774,576 | Ordinary Shares |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 29.53 per share. | 06 Nov 2024 | 10,471 | 99,238 (0%) | 0% | 29.5 | 309,169 | Ordinary Shares |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2024 | 2,014 | 4,029 | - | - | Restricted Stock Unit Award | |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2024 | 2,014 | 166,796 (0%) | 0% | - | Ordinary Shares | |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.72 per share. | 03 Aug 2024 | 895 | 165,901 (0%) | 0% | 27.7 | 24,809 | Ordinary Shares |
| Brian P. Mckeon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2024 | 6,104 | 29,245 (0%) | 0% | - | Ordinary Shares | |
| Brian P. Mckeon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2024 | 6,104 | 0 | - | - | Restricted Stock Unit Award | |
| Brian P. Mckeon | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.10 per share. | 29 Jun 2024 | 1,465 | 27,780 (0%) | 0% | 24.1 | 35,307 | Ordinary Shares |
| Cato T. Laurencin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2024 | 6,104 | 0 | - | - | Restricted Stock Unit Award | |
| Cato T. Laurencin | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.10 per share. | 29 Jun 2024 | 1,465 | 19,808 (0%) | 0% | 24.1 | 35,307 | Ordinary Shares |
| Cato T. Laurencin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2024 | 6,104 | 21,273 (0%) | 0% | - | Ordinary Shares | |
| Frank Anders Wilson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2024 | 6,104 | 0 | - | - | Restricted Stock Unit Award | |
| Frank Anders Wilson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2024 | 6,104 | 26,460 (0%) | 0% | - | Ordinary Shares | |
| Frank Anders Wilson | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.10 per share. | 29 Jun 2024 | 1,465 | 24,995 (0%) | 0% | 24.1 | 35,307 | Ordinary Shares |
| Shane M. Cooke | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.10 per share. | 29 Jun 2024 | 3,175 | 99,906 (0%) | 0% | 24.1 | 76,518 | Ordinary Shares |
| Shane M. Cooke | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2024 | 6,104 | 0 | - | - | Restricted Stock Unit Award | |
| Shane M. Cooke | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2024 | 6,104 | 103,081 (0%) | 0% | - | Ordinary Shares | |
| Nancy L. Snyderman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2024 | 6,104 | 6,104 (0%) | 0% | - | Ordinary Shares | |
| Nancy L. Snyderman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2024 | 6,104 | 0 | - | - | Restricted Stock Unit Award | |
| Nancy L. Snyderman | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.10 per share. | 29 Jun 2024 | 1,465 | 4,639 (0%) | 0% | 24.1 | 35,307 | Ordinary Shares |
| Emily Peterson Alva | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2024 | 6,104 | 28,767 (0%) | 0% | - | Ordinary Shares | |
| Emily Peterson Alva | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2024 | 6,104 | 0 | - | - | Restricted Stock Unit Award | |
| Emily Peterson Alva | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.10 per share. | 29 Jun 2024 | 1,465 | 27,302 (0%) | 0% | 24.1 | 35,307 | Ordinary Shares |
| Richard B. Gaynor | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2024 | 6,104 | 26,460 (0%) | 0% | - | Ordinary Shares | |
| Richard B. Gaynor | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2024 | 6,104 | 0 | - | - | Restricted Stock Unit Award | |
| Richard B. Gaynor | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.10 per share. | 29 Jun 2024 | 1,465 | 24,995 (0%) | 0% | 24.1 | 35,307 | Ordinary Shares |
| David A. Daglio | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2024 | 6,104 | 29,245 (0%) | 0% | - | Ordinary Shares | |
| David A. Daglio | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2024 | 6,104 | 0 | - | - | Restricted Stock Unit Award | |
| David A. Daglio | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.10 per share. | 29 Jun 2024 | 1,465 | 27,780 (0%) | 0% | 24.1 | 35,307 | Ordinary Shares |
| Christopher I. Wright | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2024 | 6,104 | 15,881 (0%) | 0% | - | Ordinary Shares | |
| Christopher I. Wright | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.10 per share. | 29 Jun 2024 | 1,465 | 14,416 (0%) | 0% | 24.1 | 35,307 | Ordinary Shares |
| Christopher I. Wright | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2024 | 6,104 | 0 | - | - | Restricted Stock Unit Award | |
| Emily Peterson Alva | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.91 per share. | 09 Jun 2024 | 930 | 22,663 (0%) | 0% | 23.9 | 22,236 | Ordinary Shares |
| Emily Peterson Alva | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2024 | 3,871 | 0 | - | - | Restricted Stock Unit Award | |
| Emily Peterson Alva | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2024 | 3,871 | 23,593 (0%) | 0% | - | Ordinary Shares | |
| Christopher I. Wright | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.91 per share. | 08 Jun 2024 | 793 | 9,777 (0%) | 0% | 23.9 | 18,961 | Ordinary Shares |
| Christopher I. Wright | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2024 | 3,301 | 3,301 | - | - | Restricted Stock Unit Award | |
| Christopher I. Wright | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2024 | 3,301 | 10,570 (0%) | 0% | - | Ordinary Shares | |
| Frank Anders Wilson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 17,492 | 17,492 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Frank Anders Wilson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 8,013 | 8,013 | - | - | Restricted Stock Unit Award | |
| Frank Anders Wilson | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 119 | 6,104 | - | - | Restricted Stock Unit Award | |
| Shane M. Cooke | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 350 | 17,850 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Shane M. Cooke | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 1,102 | 56,227 | - | - | Employee Stock Option (Right to Buy) | |
| Shane M. Cooke | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 1,200 | 61,200 | - | - | Employee Stock Option (Right to Buy) | |
| Shane M. Cooke | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 425 | 21,675 | - | - | Employee Stock Option (Right to Buy) | |
| Shane M. Cooke | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 520 | 26,520 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Shane M. Cooke | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 17,492 | 17,492 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Shane M. Cooke | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 448 | 22,848 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Shane M. Cooke | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 256 | 13,079 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Shane M. Cooke | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 230 | 11,739 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Shane M. Cooke | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 313 | 15,990 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Shane M. Cooke | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 231 | 11,785 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Shane M. Cooke | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 254 | 12,986 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Shane M. Cooke | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 119 | 6,104 | - | - | Restricted Stock Unit Award | |
| Shane M. Cooke | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 8,013 | 8,013 | - | - | Restricted Stock Unit Award | |
| Nancy L. Snyderman | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 254 | 12,986 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Nancy L. Snyderman | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 231 | 11,785 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Nancy L. Snyderman | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 313 | 15,990 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Nancy L. Snyderman | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 230 | 11,739 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Nancy L. Snyderman | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 256 | 13,079 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Nancy L. Snyderman | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 448 | 22,848 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Nancy L. Snyderman | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 350 | 17,850 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Nancy L. Snyderman | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 284 | 14,484 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Nancy L. Snyderman | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 548 | 27,948 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Nancy L. Snyderman | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 324 | 16,524 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Nancy L. Snyderman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 17,492 | 17,492 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Nancy L. Snyderman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 8,013 | 8,013 | - | - | Restricted Stock Unit Award | |
| Nancy L. Snyderman | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 119 | 6,104 | - | - | Restricted Stock Unit Award | |
| Emily Peterson Alva | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 75 | 3,871 | - | - | Restricted Stock Unit Award | |
| Emily Peterson Alva | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 17,492 | 17,492 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Emily Peterson Alva | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 8,013 | 8,013 | - | - | Restricted Stock Unit Award | |
| Emily Peterson Alva | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 119 | 6,104 | - | - | Restricted Stock Unit Award | |
| Emily Peterson Alva | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 254 | 12,986 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Emily Peterson Alva | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 231 | 11,785 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Emily Peterson Alva | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 313 | 15,990 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Emily Peterson Alva | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 455 | 23,214 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Emily Peterson Alva | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 22 | 1,137 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Richard B. Gaynor | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 1,236 | 63,036 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Richard B. Gaynor | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 224 | 11,424 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Richard B. Gaynor | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 256 | 13,079 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Richard B. Gaynor | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 230 | 11,739 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Richard B. Gaynor | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 119 | 6,104 | - | - | Restricted Stock Unit Award | |
| Richard B. Gaynor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 8,013 | 8,013 | - | - | Restricted Stock Unit Award | |
| Richard B. Gaynor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 17,492 | 17,492 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Richard B. Gaynor | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 254 | 12,986 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Richard B. Gaynor | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 231 | 11,785 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Richard B. Gaynor | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 313 | 15,990 | - | - | Non Qualified Stock Option (Right to Buy) | |
| David A. Daglio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 8,013 | 8,013 | - | - | Restricted Stock Unit Award | |
| David A. Daglio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 17,492 | 17,492 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Christopher I. Wright | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 14 | 728 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Christopher I. Wright | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 231 | 11,785 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Christopher I. Wright | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 129 | 6,602 | - | - | Restricted Stock Unit Award | |
| Christopher I. Wright | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 355 | 18,128 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Christopher I. Wright | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 254 | 12,986 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Christopher I. Wright | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 119 | 6,104 | - | - | Restricted Stock Unit Award | |
| Christopher I. Wright | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 8,013 | 8,013 | - | - | Restricted Stock Unit Award | |
| Christopher I. Wright | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 17,492 | 17,492 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Brian P. Mckeon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 17,492 | 17,492 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Brian P. Mckeon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 8,013 | 8,013 | - | - | Restricted Stock Unit Award | |
| Cato T. Laurencin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 17,492 | 17,492 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Cato T. Laurencin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 8,013 | 8,013 | - | - | Restricted Stock Unit Award | |
| Nancy S. Lurker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 17,492 | 17,492 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Nancy S. Lurker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 8,013 | 8,013 | - | - | Restricted Stock Unit Award | |
| Frank Anders Wilson | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 1,236 | 63,036 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Frank Anders Wilson | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 224 | 11,424 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Frank Anders Wilson | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 256 | 13,079 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Frank Anders Wilson | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 230 | 11,739 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Frank Anders Wilson | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 313 | 15,990 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Frank Anders Wilson | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 231 | 11,785 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Frank Anders Wilson | Director | Other type of transaction at price $ 0.00 per share. | 31 May 2024 | 254 | 12,986 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Nancy S. Lurker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Apr 2024 | 11,255 | 11,255 | - | - | Restricted Stock Unit Award | |
| Nancy S. Lurker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Apr 2024 | 2,323 | 2,323 | - | - | Restricted Stock Unit Award | |
| Nancy S. Lurker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Apr 2024 | 22,103 | 22,103 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Nancy S. Lurker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Apr 2024 | 4,833 | 4,833 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Christian Todd Nichols | SVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 28.10 per share. | 18 Mar 2024 | 10,417 | 65,911 (0%) | 0% | 28.1 | 292,740 | Ordinary Shares |
| Richard F. Pops | Director, Director and CEO, Alkermes plc | Other type of transaction at price $ 0.00 per share. | 26 Feb 2024 | 2,419 | 123,419 | - | - | Employee Stock Option (Right to Buy) | |
| Pops Richard F. | Director, Director and CEO, Alkermes plc | Other type of transaction at price $ 0.00 per share. | 26 Feb 2024 | 3,999 | 203,999 | - | - | Employee Stock Option (Right to Buy) | |
| Pops Richard F. | Director, Director and CEO, Alkermes plc | Other type of transaction at price $ 0.00 per share. | 26 Feb 2024 | 5,697 | 290,570 | - | - | Employee Stock Option (Right to Buy) | |
| Richard F. Pops | Director, Director and CEO, Alkermes plc | Other type of transaction at price $ 0.00 per share. | 26 Feb 2024 | 7,168 | 365,634 | - | - | Employee Stock Option (Right to Buy) | |
| Pops F. Richard | Director, Director and CEO, Alkermes plc | Other type of transaction at price $ 0.00 per share. | 26 Feb 2024 | 4,599 | 234,599 | - | - | Employee Stock Option (Right to Buy) | |
| Pops F. Richard | Director, Director and CEO, Alkermes plc | Other type of transaction at price $ 0.00 per share. | 26 Feb 2024 | 5,999 | 305,999 | - | - | Employee Stock Option (Right to Buy) | |
| Pops F. Richard | Director, Director and CEO, Alkermes plc | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 274,328 | 274,328 | - | - | Employee Stock Option (Right to Buy) | |
| Richard F. Pops | Director, Director and CEO, Alkermes plc | Other type of transaction at price $ 0.00 per share. | 26 Feb 2024 | 5,980 | 305,024 | - | - | Employee Stock Option (Right to Buy) | |
| Richard Pops F. | Director, Director and CEO, Alkermes plc | Other type of transaction at price $ 0.00 per share. | 26 Feb 2024 | 3,999 | 203,999 | - | - | Employee Stock Option (Right to Buy) | |
| Pops Richard F. | Director, Director and CEO, Alkermes plc | Other type of transaction at price $ 0.00 per share. | 26 Feb 2024 | 5,899 | 300,899 | - | - | Employee Stock Option (Right to Buy) | |
| Richard Pops F. | Director, Director and CEO, Alkermes plc | Other type of transaction at price $ 0.00 per share. | 26 Feb 2024 | 7,644 | 389,844 | - | - | Employee Stock Option (Right to Buy) | |
| F. Pops Richard | Director, Director and CEO, Alkermes plc | Other type of transaction at price $ 0.00 per share. | 26 Feb 2024 | 6,843 | 349,030 | - | - | Employee Stock Option (Right to Buy) | |
| Joseph Gaffin David | EVP, CLO, Alkermes, Inc. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 27,464 | 27,464 | - | - | Restricted Stock Unit Award | |
| Samuel Parisi J. | VP, Finance (Interim PAO) | Sale of securities on an exchange or to another person at price $ 29.65 per share. | 23 Feb 2024 | 2,559 | 7,717 (0%) | 0% | 29.6 | 75,874 | Ordinary Shares |
| Blair C. Jackson | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 8,737 | 161,682 (0%) | 0% | - | Ordinary Shares | |
| C. Blair Jackson | EVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 33,289 | 33,289 | - | - | Restricted Stock Unit Award | |
| Samuel Parisi J. | VP, Finance (Interim PAO) | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.57 per share. | 23 Feb 2024 | 672 | 10,276 (0%) | 0% | 29.6 | 19,871 | Ordinary Shares |
| C. Blair Jackson | EVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 134,771 | 134,771 | - | - | Employee Stock Option (Right to Buy) | |
| Christian Todd Nichols | SVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 87,602 | 87,602 | - | - | Employee Stock Option (Right to Buy) | |
| M. Brown Iain | SVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 5,825 | 118,931 (0%) | 0% | - | Ordinary Shares | |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 111,186 | 111,186 | - | - | Employee Stock Option (Right to Buy) | |
| Landine J. Michael | SVP, Corp Dev., Alkermes, Inc. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.57 per share. | 23 Feb 2024 | 1,811 | 281,730 (0%) | 0% | 29.6 | 53,551 | Ordinary Shares |
| Christian Nichols Todd | SVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.57 per share. | 23 Feb 2024 | 2,845 | 76,328 (0%) | 0% | 29.6 | 84,127 | Ordinary Shares |
| M. Iain Brown | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 90,971 | 90,971 | - | - | Employee Stock Option (Right to Buy) | |
| Joseph Gaffin David | EVP, CLO, Alkermes, Inc. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.57 per share. | 23 Feb 2024 | 3,414 | 164,782 (0%) | 0% | 29.6 | 100,952 | Ordinary Shares |
| Samuel J. Parisi | VP, Finance (Interim PAO) | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 10,986 | 10,986 | - | - | Restricted Stock Unit Award | |
| Blair Jackson C. | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.57 per share. | 23 Feb 2024 | 3,880 | 157,802 (0%) | 0% | 29.6 | 114,732 | Ordinary Shares |
| Samuel J. Parisi | VP, Finance (Interim PAO) | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 2,283 | 10,948 (0%) | 0% | - | Ordinary Shares | |
| Todd Christian Nichols | SVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 6,407 | 79,173 (0%) | 0% | - | Ordinary Shares | |
| Joseph Gaffin David | EVP, CLO, Alkermes, Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 7,689 | 168,196 (0%) | 0% | - | Ordinary Shares | |
| Samuel Parisi J. | VP, Finance (Interim PAO) | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 2,283 | 6,851 | - | - | Restricted Stock Unit Award | |
| C. Hopkinson Craig | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 7,689 | 23,068 | - | - | Restricted Stock Unit Award | |
| Brown M. Iain | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 22,471 | 22,471 | - | - | Restricted Stock Unit Award | |
| Samuel Parisi J. | VP, Finance (Interim PAO) | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 20,890 | 20,890 | - | - | Employee Stock Option (Right to Buy) | |
| Joseph Gaffin David | EVP, CLO, Alkermes, Inc. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 111,186 | 111,186 | - | - | Employee Stock Option (Right to Buy) | |
| Landine Michael J. | SVP, Corp Dev., Alkermes, Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 4,077 | 283,541 (0%) | 0% | - | Ordinary Shares | |
| Landine Michael J. | SVP, Corp Dev., Alkermes, Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 4,077 | 12,233 | - | - | Restricted Stock Unit Award | |
| C. Hopkinson Craig | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.57 per share. | 23 Feb 2024 | 3,414 | 109,709 (0%) | 0% | 29.6 | 100,952 | Ordinary Shares |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 7,689 | 113,123 (0%) | 0% | - | Ordinary Shares | |
| Iain Brown M. | SVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 5,825 | 17,475 | - | - | Restricted Stock Unit Award | |
| Christian Todd Nichols | SVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 6,407 | 19,223 | - | - | Restricted Stock Unit Award | |
| Craig Hopkinson C. | EVP R&D, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 27,464 | 27,464 | - | - | Restricted Stock Unit Award | |
| Jackson C. Blair | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 8,737 | 26,214 | - | - | Restricted Stock Unit Award | |
| Todd Nichols Christian | SVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 21,638 | 21,638 | - | - | Restricted Stock Unit Award | |
| Gaffin Joseph David | EVP, CLO, Alkermes, Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 7,689 | 23,068 | - | - | Restricted Stock Unit Award | |
| M. Iain Brown | SVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.57 per share. | 23 Feb 2024 | 2,587 | 116,344 (0%) | 0% | 29.6 | 76,498 | Ordinary Shares |
| Jackson Blair C. | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2024 | 9,693 | 157,249 (0%) | 0% | - | Ordinary Shares | |
| Christian Todd Nichols | SVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2024 | 7,108 | 7,109 | - | - | Restricted Stock Unit Award | |
| M. Iain Brown | SVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2024 | 7,108 | 116,262 (0%) | 0% | - | Ordinary Shares | |
| J. Samuel Parisi | VP, Finance (Interim PAO) | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.91 per share. | 22 Feb 2024 | 908 | 8,665 (0%) | 0% | 28.9 | 26,250 | Ordinary Shares |
| C. Blair Jackson | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.91 per share. | 22 Feb 2024 | 4,304 | 152,945 (0%) | 0% | 28.9 | 124,429 | Ordinary Shares |
| M. Brown Iain | SVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2024 | 7,108 | 7,109 | - | - | Restricted Stock Unit Award | |
| Landine J. Michael | SVP, Corp Dev., Alkermes, Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2024 | 5,654 | 5,655 | - | - | Restricted Stock Unit Award | |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.91 per share. | 22 Feb 2024 | 3,300 | 160,507 (0%) | 0% | 28.9 | 95,403 | Ordinary Shares |
| Todd Nichols Christian | SVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2024 | 7,108 | 75,922 (0%) | 0% | - | Ordinary Shares | |
| Nichols Christian Todd | SVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.91 per share. | 22 Feb 2024 | 3,156 | 72,766 (0%) | 0% | 28.9 | 91,240 | Ordinary Shares |
| Hopkinson C. Craig | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.91 per share. | 22 Feb 2024 | 5,452 | 105,434 (0%) | 0% | 28.9 | 157,617 | Ordinary Shares |
| J. Michael Landine | SVP, Corp Dev., Alkermes, Inc. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.91 per share. | 22 Feb 2024 | 1,929 | 279,464 (0%) | 0% | 28.9 | 55,767 | Ordinary Shares |
| Parisi Samuel J. | VP, Finance (Interim PAO) | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2024 | 3,114 | 3,114 | - | - | Restricted Stock Unit Award | |
| Samuel Parisi J. | VP, Finance (Interim PAO) | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2024 | 3,114 | 9,573 (0%) | 0% | - | Ordinary Shares | |
| Craig Hopkinson C. | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2024 | 12,278 | 12,279 | - | - | Restricted Stock Unit Award | |
| J. Michael Landine | SVP, Corp Dev., Alkermes, Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2024 | 5,654 | 281,393 (0%) | 0% | - | Ordinary Shares | |
| Hopkinson C. Craig | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2024 | 12,278 | 110,886 (0%) | 0% | - | Ordinary Shares | |
| Brown M. Iain | SVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.91 per share. | 22 Feb 2024 | 3,156 | 113,106 (0%) | 0% | 28.9 | 91,240 | Ordinary Shares |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2024 | 7,431 | 7,432 | - | - | Restricted Stock Unit Award | |
| Joseph David Gaffin | EVP, CLO, Alkermes, Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2024 | 7,431 | 163,807 (0%) | 0% | - | Ordinary Shares | |
| Jackson C. Blair | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2024 | 9,693 | 9,694 | - | - | Restricted Stock Unit Award | |
| Parisi J. Samuel | VP, Finance (Interim PAO) | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.39 per share. | 18 Feb 2024 | 641 | 6,459 (0%) | 0% | 30.4 | 19,480 | Ordinary Shares |
| Nichols Todd Christian | SVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 18 Feb 2024 | 2,274 | 116,028 | - | - | Employee Stock Option (Right to Buy) | |
| Michael Landine J. | SVP, Corp Dev., Alkermes, Inc. | Other type of transaction at price $ 0.00 per share. | 18 Feb 2024 | 261 | 13,345 | - | - | Restricted Stock Unit Award | |
| Nichols Christian Todd | SVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 18 Feb 2024 | 373 | 19,064 | - | - | Restricted Stock Unit Award | |
| M. Iain Brown | SVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.39 per share. | 18 Feb 2024 | 1,725 | 109,154 (0%) | 0% | 30.4 | 52,423 | Ordinary Shares |
| Hopkinson C. Craig | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 8,897 | 96,834 (0%) | 0% | - | Ordinary Shares | |
| Michael Landine J. | SVP, Corp Dev., Alkermes, Inc. | Other type of transaction at price $ 0.00 per share. | 18 Feb 2024 | 1,394 | 71,171 | - | - | Employee Stock Option (Right to Buy) | |
| Blair Jackson C. | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.39 per share. | 18 Feb 2024 | 2,078 | 147,556 (0%) | 0% | 30.4 | 63,150 | Ordinary Shares |
| J. Landine Michael | SVP, Corp Dev., Alkermes, Inc. | Other type of transaction at price $ 0.00 per share. | 18 Feb 2024 | 1,279 | 65,241 | - | - | Employee Stock Option (Right to Buy) | |
| Christian Todd Nichols | SVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 18 Feb 2024 | 278 | 14,217 | - | - | Restricted Stock Unit Award | |
| Todd Nichols Christian | SVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.18 per share. | 18 Feb 2024 | 1,869 | 66,292 (0%) | 0% | 32.2 | 60,144 | Ordinary Shares |
| Samuel J. Parisi | VP, Finance (Interim PAO) | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 2,034 | 4,067 | - | - | Restricted Stock Unit Award | |
| Hopkinson C. Craig | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 8,897 | 17,793 | - | - | Restricted Stock Unit Award | |
| J. Parisi Samuel | VP, Finance (Interim PAO) | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 2,034 | 5,934 (0%) | 0% | - | Ordinary Shares | |
| Michael Landine J. | SVP, Corp Dev., Alkermes, Inc. | Other type of transaction at price $ 0.00 per share. | 18 Feb 2024 | 1,811 | 92,411 | - | - | Employee Stock Option (Right to Buy) | |
| Joseph Gaffin David | EVP, CLO, Alkermes, Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 7,177 | 0 | - | - | Restricted Stock Unit Award | |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 10,297 | 103,180 (0%) | 0% | - | Ordinary Shares | |
| Michael J. Landine | SVP, Corp Dev., Alkermes, Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 4,448 | 8,897 | - | - | Restricted Stock Unit Award | |
| J. Michael Landine | SVP, Corp Dev., Alkermes, Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 5,461 | 0 | - | - | Restricted Stock Unit Award | |
| Nichols Christian Todd | SVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 18 Feb 2024 | 502 | 25,630 | - | - | Restricted Stock Unit Award | |
| Christian Nichols Todd | SVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 18 Feb 2024 | 1,992 | 101,674 | - | - | Employee Stock Option (Right to Buy) | |
| C. Blair Jackson | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 4,680 | 149,634 (0%) | 0% | - | Ordinary Shares | |
| J. Samuel Parisi | VP, Finance (Interim PAO) | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.18 per share. | 18 Feb 2024 | 706 | 5,228 (0%) | 0% | 32.2 | 22,719 | Ordinary Shares |
| Todd Christian Nichols | SVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 6,355 | 68,161 (0%) | 0% | - | Ordinary Shares | |
| J. Landine Michael | SVP, Corp Dev., Alkermes, Inc. | Other type of transaction at price $ 0.00 per share. | 18 Feb 2024 | 1,089 | 55,589 | - | - | Employee Stock Option (Right to Buy) | |
| J. Landine Michael | SVP, Corp Dev., Alkermes, Inc. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.39 per share. | 18 Feb 2024 | 1,606 | 275,739 (0%) | 0% | 30.4 | 48,806 | Ordinary Shares |
| Christian Todd Nichols | SVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 6,355 | 12,709 | - | - | Restricted Stock Unit Award | |
| Nichols Todd Christian | SVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 18 Feb 2024 | 885 | 45,212 | - | - | Employee Stock Option (Right to Buy) | |
| C. Jackson Blair | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 8,897 | 17,793 | - | - | Restricted Stock Unit Award | |
| Todd Nichols Christian | SVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 3,901 | 0 | - | - | Restricted Stock Unit Award | |
| Christian Nichols Todd | SVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 18 Feb 2024 | 999 | 50,999 | - | - | Employee Stock Option (Right to Buy) | |
| J. Landine Michael | SVP, Corp Dev., Alkermes, Inc. | Other type of transaction at price $ 0.00 per share. | 18 Feb 2024 | 1,790 | 91,335 | - | - | Employee Stock Option (Right to Buy) | |
| C. Blair Jackson | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 4,680 | 0 | - | - | Restricted Stock Unit Award | |
| Blair Jackson C. | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 8,897 | 148,842 (0%) | 0% | - | Ordinary Shares | |
| J. Parisi Samuel | VP, Finance (Interim PAO) | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 1,872 | 0 | - | - | Restricted Stock Unit Award | |
| Todd Christian Nichols | SVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 18 Feb 2024 | 76 | 3,901 | - | - | Restricted Stock Unit Award | |
| Brown M. Iain | SVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 4,680 | 0 | - | - | Restricted Stock Unit Award | |
| Nichols Christian Todd | SVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 3,901 | 70,193 (0%) | 0% | - | Ordinary Shares | |
| Hopkinson C. Craig | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.18 per share. | 18 Feb 2024 | 3,951 | 92,883 (0%) | 0% | 32.2 | 127,143 | Ordinary Shares |
| Michael Landine J. | SVP, Corp Dev., Alkermes, Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 5,461 | 277,345 (0%) | 0% | - | Ordinary Shares | |
| Christian Todd Nichols | SVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.39 per share. | 18 Feb 2024 | 1,379 | 68,814 (0%) | 0% | 30.4 | 41,908 | Ordinary Shares |
| Iain M. Brown | SVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 4,680 | 110,879 (0%) | 0% | - | Ordinary Shares | |
| David Gaffin Joseph | EVP, CLO, Alkermes, Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 6,355 | 154,062 (0%) | 0% | - | Ordinary Shares | |
| J. Landine Michael | SVP, Corp Dev., Alkermes, Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 4,448 | 273,192 (0%) | 0% | - | Ordinary Shares | |
| Landine Michael J. | SVP, Corp Dev., Alkermes, Inc. | Other type of transaction at price $ 0.00 per share. | 18 Feb 2024 | 999 | 50,999 | - | - | Employee Stock Option (Right to Buy) | |
| C. Hopkinson Craig | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 10,297 | 0 | - | - | Restricted Stock Unit Award | |
| C. Craig Hopkinson | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.39 per share. | 18 Feb 2024 | 4,572 | 98,608 (0%) | 0% | 30.4 | 138,943 | Ordinary Shares |
| Joseph David Gaffin | EVP, CLO, Alkermes, Inc. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.39 per share. | 18 Feb 2024 | 2,994 | 156,376 (0%) | 0% | 30.4 | 90,988 | Ordinary Shares |
| Joseph David Gaffin | EVP, CLO, Alkermes, Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 7,177 | 159,370 (0%) | 0% | - | Ordinary Shares | |
| Landine J. Michael | SVP, Corp Dev., Alkermes, Inc. | Other type of transaction at price $ 0.00 per share. | 18 Feb 2024 | 1,809 | 92,296 | - | - | Employee Stock Option (Right to Buy) | |
| Michael J. Landine | SVP, Corp Dev., Alkermes, Inc. | Other type of transaction at price $ 0.00 per share. | 18 Feb 2024 | 879 | 44,879 | - | - | Employee Stock Option (Right to Buy) | |
| J. Landine Michael | SVP, Corp Dev., Alkermes, Inc. | Other type of transaction at price $ 0.00 per share. | 18 Feb 2024 | 319 | 16,310 | - | - | Restricted Stock Unit Award | |
| Jackson C. Blair | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.18 per share. | 18 Feb 2024 | 3,888 | 144,954 (0%) | 0% | 32.2 | 125,116 | Ordinary Shares |
| Samuel J. Parisi | VP, Finance (Interim PAO) | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 1,872 | 7,100 (0%) | 0% | - | Ordinary Shares | |
| J. Michael Landine | SVP, Corp Dev., Alkermes, Inc. | Other type of transaction at price $ 0.00 per share. | 18 Feb 2024 | 107 | 5,461 | - | - | Restricted Stock Unit Award | |
| M. Brown Iain | SVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.18 per share. | 18 Feb 2024 | 1,869 | 106,199 (0%) | 0% | 32.2 | 60,144 | Ordinary Shares |
| Joseph Gaffin David | EVP, CLO, Alkermes, Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 6,355 | 12,709 | - | - | Restricted Stock Unit Award | |
| Gaffin Joseph David | EVP, CLO, Alkermes, Inc. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.18 per share. | 18 Feb 2024 | 1,869 | 152,193 (0%) | 0% | 32.2 | 60,144 | Ordinary Shares |
| J. Michael Landine | SVP, Corp Dev., Alkermes, Inc. | Other type of transaction at price $ 0.00 per share. | 18 Feb 2024 | 221 | 11,309 | - | - | Restricted Stock Unit Award | |
| Christian Nichols Todd | SVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 18 Feb 2024 | 2,010 | 102,522 | - | - | Employee Stock Option (Right to Buy) | |
| Landine J. Michael | SVP, Corp Dev., Alkermes, Inc. | Other type of transaction at price $ 0.00 per share. | 18 Feb 2024 | 1,519 | 77,519 | - | - | Employee Stock Option (Right to Buy) | |
| J. Michael Landine | SVP, Corp Dev., Alkermes, Inc. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.18 per share. | 18 Feb 2024 | 1,308 | 271,884 (0%) | 0% | 32.2 | 42,091 | Ordinary Shares |
| Brown Iain M. | SVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 6,355 | 12,709 | - | - | Restricted Stock Unit Award | |
| Brown Iain M. | SVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 6,355 | 108,068 (0%) | 0% | - | Ordinary Shares | |
| Michael Landine J. | SVP, Corp Dev., Alkermes, Inc. | Other type of transaction at price $ 0.00 per share. | 18 Feb 2024 | 999 | 50,999 | - | - | Employee Stock Option (Right to Buy) | |
| Cato T. Laurencin | Director | Sale of securities on an exchange or to another person at price $ 31.85 per share. | 15 Feb 2024 | 2,690 | 15,169 (0%) | 0% | 31.9 | 85,677 | Ordinary Shares |
| Laurencin Cato T. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.52 per share. | 15 Feb 2024 | 2,690 | 17,859 (0%) | 0% | 22.5 | 60,579 | Ordinary Shares |
| Laurencin T. Cato | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 2,690 | 18,833 | - | - | Non Qualified Stock Option (Right to Buy) | |
| P. Brian Mckeon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2024 | 4,533 | 0 | - | - | Restricted Stock Unit Award | |
| Daglio David A. | Director | Other type of transaction at price $ 0.00 per share. | 10 Feb 2024 | 88 | 4,533 | - | - | Restricted Stock Unit Award | |
| P. Mckeon Brian | Director | Other type of transaction at price $ 0.00 per share. | 10 Feb 2024 | 88 | 4,533 | - | - | Restricted Stock Unit Award | |
| P. Brian Mckeon | Director | Other type of transaction at price $ 0.00 per share. | 10 Feb 2024 | 90 | 4,639 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Mckeon P. Brian | Director | Other type of transaction at price $ 0.00 per share. | 10 Feb 2024 | 254 | 12,986 | - | - | Non Qualified Stock Option (Right to Buy) | |
| P. Mckeon Brian | Director | Other type of transaction at price $ 0.00 per share. | 10 Feb 2024 | 119 | 6,104 | - | - | Restricted Stock Unit Award | |
| Brian P. Mckeon | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.32 per share. | 10 Feb 2024 | 1,088 | 23,141 (0%) | 0% | 27.3 | 29,724 | Ordinary Shares |
| Daglio David A. | Director | Other type of transaction at price $ 0.00 per share. | 10 Feb 2024 | 254 | 12,986 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Daglio David A. | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.32 per share. | 10 Feb 2024 | 1,088 | 23,141 (0%) | 0% | 27.3 | 29,724 | Ordinary Shares |
| David A. Daglio | Director | Other type of transaction at price $ 0.00 per share. | 10 Feb 2024 | 231 | 11,785 | - | - | Non Qualified Stock Option (Right to Buy) | |
| A. Daglio David | Director | Other type of transaction at price $ 0.00 per share. | 10 Feb 2024 | 313 | 15,990 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Daglio A. David | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2024 | 4,533 | 0 | - | - | Restricted Stock Unit Award | |
| David A. Daglio | Director | Other type of transaction at price $ 0.00 per share. | 10 Feb 2024 | 90 | 4,639 | - | - | Non Qualified Stock Option (Right to Buy) | |
| A. David Daglio | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2024 | 4,533 | 24,229 (0%) | 0% | - | Ordinary Shares | |
| Brian Mckeon P. | Director | Other type of transaction at price $ 0.00 per share. | 10 Feb 2024 | 231 | 11,785 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Mckeon Brian P. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2024 | 4,533 | 24,229 (0%) | 0% | - | Ordinary Shares | |
| P. Mckeon Brian | Director | Other type of transaction at price $ 0.00 per share. | 10 Feb 2024 | 313 | 15,990 | - | - | Non Qualified Stock Option (Right to Buy) | |
| P. Brian Mckeon | Director | Other type of transaction at price $ 0.00 per share. | 10 Feb 2024 | 523 | 26,692 | - | - | Non Qualified Stock Option (Right to Buy) | |
| David Daglio A. | Director | Other type of transaction at price $ 0.00 per share. | 10 Feb 2024 | 119 | 6,104 | - | - | Restricted Stock Unit Award | |
| David Daglio A. | Director | Other type of transaction at price $ 0.00 per share. | 10 Feb 2024 | 523 | 26,692 | - | - | Non Qualified Stock Option (Right to Buy) | |
| C. Jackson Blair | EVP, Chief Operating Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 899 | 45,899 | - | - | Employee Stock Option (Right to Buy) | |
| Joseph David Gaffin | EVP, CLO, Alkermes, Inc. | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 118 | 6,043 | - | - | Restricted Stock Unit Award | |
| Hopkinson C. Craig | EVP R&D, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 46,658 | 103,217 (0%) | 0% | - | Ordinary Shares | |
| Brown M. Iain | SVP, Chief Financial Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 499 | 25,499 | - | - | Employee Stock Option (Right to Buy) | |
| Michael J. Landine | SVP, Corp Dev., Alkermes, Inc. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.77 per share. | 08 Feb 2024 | 3,183 | 268,744 (0%) | 0% | 26.8 | 85,209 | Ordinary Shares |
| C. Craig Hopkinson | EVP R&D, Chief Medical Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 201 | 10,297 | - | - | Restricted Stock Unit Award | |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 3,929 | 200,413 | - | - | Employee Stock Option (Right to Buy) | |
| C. Jackson Blair | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.77 per share. | 08 Feb 2024 | 11,007 | 139,945 (0%) | 0% | 26.8 | 294,657 | Ordinary Shares |
| Iain Brown M. | SVP, Chief Financial Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 1,827 | 93,202 | - | - | Employee Stock Option (Right to Buy) | |
| M. Brown Iain | SVP, Chief Financial Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 1,534 | 78,287 | - | - | Employee Stock Option (Right to Buy) | |
| Craig Hopkinson C. | EVP R&D, Chief Medical Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 481 | 24,557 | - | - | Restricted Stock Unit Award | |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 2,790 | 142,344 | - | - | Employee Stock Option (Right to Buy) | |
| Craig Hopkinson C. | EVP R&D, Chief Medical Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 603 | 30,757 | - | - | Restricted Stock Unit Award | |
| Brown M. Iain | SVP, Chief Financial Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 1,992 | 101,674 | - | - | Employee Stock Option (Right to Buy) | |
| Brown M. Iain | SVP, Chief Financial Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 456 | 23,300 | - | - | Restricted Stock Unit Award | |
| Hopkinson C. Craig | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.77 per share. | 08 Feb 2024 | 15,280 | 87,937 (0%) | 0% | 26.8 | 409,046 | Ordinary Shares |
| Blair Jackson C. | EVP, Chief Operating Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 685 | 34,951 | - | - | Restricted Stock Unit Award | |
| Joseph Gaffin David | EVP, CLO, Alkermes, Inc. | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 1,992 | 101,674 | - | - | Employee Stock Option (Right to Buy) | |
| Blair Jackson C. | EVP, Chief Operating Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 2,790 | 142,344 | - | - | Employee Stock Option (Right to Buy) | |
| M. Iain Brown | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 27,012 | 109,850 (0%) | 0% | - | Ordinary Shares | |
| Gaffin Joseph David | EVP, CLO, Alkermes, Inc. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.77 per share. | 08 Feb 2024 | 8,483 | 147,707 (0%) | 0% | 26.8 | 227,090 | Ordinary Shares |
| David Gaffin Joseph | EVP, CLO, Alkermes, Inc. | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 2,133 | 108,833 | - | - | Employee Stock Option (Right to Buy) | |
| F. Richard Pops | Director, Director and CEO, Alkermes plc | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 218,551 | 1,271,432 (0%) | 0% | - | Ordinary Shares | |
| C. Blair Jackson | EVP, Chief Operating Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 3,102 | 158,221 | - | - | Employee Stock Option (Right to Buy) | |
| C. Blair Jackson | EVP, Chief Operating Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 380 | 19,387 | - | - | Restricted Stock Unit Award | |
| M. Iain Brown | SVP, Chief Financial Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 759 | 38,759 | - | - | Employee Stock Option (Right to Buy) | |
| Jackson Blair C. | EVP, Chief Operating Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 91 | 4,680 | - | - | Restricted Stock Unit Award | |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 719 | 36,719 | - | - | Employee Stock Option (Right to Buy) | |
| Blair C. Jackson | EVP, Chief Operating Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 1,534 | 78,287 | - | - | Employee Stock Option (Right to Buy) | |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 354 | 18,104 | - | - | Employee Stock Option (Right to Buy) | |
| Brown M. Iain | SVP, Chief Financial Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 1,489 | 75,989 | - | - | Employee Stock Option (Right to Buy) | |
| Hopkinson C. Craig | EVP R&D, Chief Medical Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 2,133 | 108,833 | - | - | Employee Stock Option (Right to Buy) | |
| Iain M. Brown | SVP, Chief Financial Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 278 | 14,217 | - | - | Restricted Stock Unit Award | |
| Blair C. Jackson | EVP, Chief Operating Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 599 | 30,599 | - | - | Employee Stock Option (Right to Buy) | |
| Joseph Gaffin David | EVP, CLO, Alkermes, Inc. | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 603 | 30,757 | - | - | Restricted Stock Unit Award | |
| Brown Iain M. | SVP, Chief Financial Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 719 | 36,719 | - | - | Employee Stock Option (Right to Buy) | |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 576 | 29,388 | - | - | Employee Stock Option (Right to Buy) | |
| C. Blair Jackson | EVP, Chief Operating Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 759 | 38,759 | - | - | Employee Stock Option (Right to Buy) | |
| Brown M. Iain | SVP, Chief Financial Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 373 | 19,064 | - | - | Restricted Stock Unit Award | |
| Iain Brown M. | SVP, Chief Financial Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 91 | 4,680 | - | - | Restricted Stock Unit Award | |
| Blair Jackson C. | EVP, Chief Operating Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 699 | 35,699 | - | - | Employee Stock Option (Right to Buy) | |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 2,378 | 121,303 | - | - | Employee Stock Option (Right to Buy) | |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 1,089 | 55,589 | - | - | Employee Stock Option (Right to Buy) | |
| C. Hopkinson Craig | EVP R&D, Chief Medical Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 3,376 | 172,232 | - | - | Employee Stock Option (Right to Buy) | |
| C. Jackson Blair | EVP, Chief Operating Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 2,741 | 139,803 | - | - | Employee Stock Option (Right to Buy) | |
| Blair C. Jackson | EVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 36,835 | 150,952 (0%) | 0% | - | Ordinary Shares | |
| Brown M. Iain | SVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.77 per share. | 08 Feb 2024 | 8,137 | 101,713 (0%) | 0% | 26.8 | 217,827 | Ordinary Shares |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 140 | 7,177 | - | - | Restricted Stock Unit Award | |
| David Gaffin Joseph | EVP, CLO, Alkermes, Inc. | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 799 | 40,799 | - | - | Employee Stock Option (Right to Buy) | |
| C. Blair Jackson | EVP, Chief Operating Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 1,489 | 75,989 | - | - | Employee Stock Option (Right to Buy) | |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 2,412 | 123,027 | - | - | Employee Stock Option (Right to Buy) | |
| M. Iain Brown | SVP, Chief Financial Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 354 | 18,104 | - | - | Employee Stock Option (Right to Buy) | |
| Brown M. Iain | SVP, Chief Financial Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 2,274 | 116,028 | - | - | Employee Stock Option (Right to Buy) | |
| M. Brown Iain | SVP, Chief Financial Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 799 | 40,799 | - | - | Employee Stock Option (Right to Buy) | |
| Joseph Gaffin David | EVP, CLO, Alkermes, Inc. | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 291 | 14,863 | - | - | Restricted Stock Unit Award | |
| Todd Christian Nichols | SVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 27,012 | 69,941 (0%) | 0% | - | Ordinary Shares | |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 1,599 | 81,599 | - | - | Employee Stock Option (Right to Buy) | |
| Craig Hopkinson C. | EVP R&D, Chief Medical Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 523 | 26,690 | - | - | Restricted Stock Unit Award | |
| J. Michael Landine | SVP, Corp Dev., Alkermes, Inc. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 21,485 | 271,927 (0%) | 0% | - | Ordinary Shares | |
| Joseph David Gaffin | EVP, CLO, Alkermes, Inc. | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 499 | 25,499 | - | - | Employee Stock Option (Right to Buy) | |
| Jackson Blair C. | EVP, Chief Operating Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 469 | 23,969 | - | - | Employee Stock Option (Right to Buy) | |
| Todd Nichols Christian | SVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.77 per share. | 08 Feb 2024 | 8,135 | 61,806 (0%) | 0% | 26.8 | 217,774 | Ordinary Shares |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 28,240 | 156,190 (0%) | 0% | - | Ordinary Shares | |
| Joseph Gaffin David | EVP, CLO, Alkermes, Inc. | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 2,352 | 120,040 | - | - | Employee Stock Option (Right to Buy) | |
| Joseph Gaffin David | EVP, CLO, Alkermes, Inc. | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 373 | 19,064 | - | - | Restricted Stock Unit Award | |
| C. Hopkinson Craig | EVP R&D, Chief Medical Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 1,089 | 55,589 | - | - | Employee Stock Option (Right to Buy) | |
| C. Jackson Blair | EVP, Chief Operating Officer | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 523 | 26,690 | - | - | Restricted Stock Unit Award | |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Other type of transaction at price $ 0.00 per share. | 08 Feb 2024 | 2,412 | 123,027 | - | - | Employee Stock Option (Right to Buy) | |
| F. Pops Richard | Director, Director and CEO, Alkermes plc | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.77 per share. | 08 Feb 2024 | 91,757 | 1,179,675 (0%) | 0% | 26.8 | 2,456,335 | Ordinary Shares |
| T. Laurencin Cato | Director | Other type of transaction at price $ 0.00 per share. | 08 Dec 2023 | 422 | 21,523 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Cato Laurencin T. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2023 | 4,163 | 4,163 | - | - | Restricted Stock Unit Award | |
| Laurencin T. Cato | Director | Other type of transaction at price $ 0.00 per share. | 08 Dec 2023 | 254 | 12,986 | - | - | Non Qualified Stock Option (Right to Buy) | |
| T. Laurencin Cato | Director | Other type of transaction at price $ 0.00 per share. | 08 Dec 2023 | 231 | 11,785 | - | - | Non Qualified Stock Option (Right to Buy) | |
| T. Cato Laurencin | Director | Other type of transaction at price $ 0.00 per share. | 08 Dec 2023 | 119 | 6,104 | - | - | Restricted Stock Unit Award | |
| Cato Laurencin T. | Director | Other type of transaction at price $ 0.00 per share. | 08 Dec 2023 | 163 | 8,326 | - | - | Restricted Stock Unit Award | |
| Laurencin Cato T. | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.86 per share. | 08 Dec 2023 | 1,000 | 15,169 (0%) | 0% | 25.9 | 25,860 | Ordinary Shares |
| Cato T. Laurencin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2023 | 4,163 | 16,169 (0%) | 0% | - | Ordinary Shares | |
| T. Cato Laurencin | Director | Other type of transaction at price $ 0.00 per share. | 08 Dec 2023 | 112 | 5,712 | - | - | Non Qualified Stock Option (Right to Buy) | |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2023 | 1,974 | 128,827 (0%) | 0% | - | Ordinary Shares | |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2023 | 1,974 | 5,925 | - | - | Restricted Stock Unit Award | |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.63 per share. | 03 Aug 2023 | 877 | 127,950 (0%) | 0% | 27.6 | 24,232 | Ordinary Shares |
| Brian P. Mckeon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2023 | 5,957 | 0 | - | - | Restricted Stock Unit Award | |
| Brian P. Mckeon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2023 | 5,957 | 21,126 (0%) | 0% | - | Ordinary Shares | |
| Brian P. Mckeon | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.88 per share. | 07 Jul 2023 | 1,430 | 19,696 (0%) | 0% | 29.9 | 42,728 | Ordinary Shares |
| Cato T. Laurencin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2023 | 5,957 | 0 | - | - | Restricted Stock Unit Award | |
| Cato T. Laurencin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2023 | 5,957 | 13,436 (0%) | 0% | - | Ordinary Shares | |
| Cato T. Laurencin | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.88 per share. | 07 Jul 2023 | 1,430 | 12,006 (0%) | 0% | 29.9 | 42,728 | Ordinary Shares |
| Nancy J. Wysenski | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2023 | 5,957 | 21,786 (0%) | 0% | - | Ordinary Shares | |
| Nancy J. Wysenski | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2023 | 5,957 | 0 | - | - | Restricted Stock Unit Award | |
| Nancy J. Wysenski | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.88 per share. | 07 Jul 2023 | 1,430 | 20,356 (0%) | 0% | 29.9 | 42,728 | Ordinary Shares |
| Frank Anders Wilson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2023 | 5,957 | 21,786 (0%) | 0% | - | Ordinary Shares |